Document is current
Any future updates will be listed below
-
Authors
Khadka, Prasidda http://orcid.org/0000-0002-3732-7600
Reitman, Zachary J.
Lu, Sophie
Buchan, Graham
Gionet, Gabrielle
Dubois, Frank
Carvalho, Diana M. http://orcid.org/0000-0001-6881-6151
Shih, Juliann http://orcid.org/0000-0002-4086-8651
Zhang, Shu
Greenwald, Noah F.
Zack, Travis
Shapira, Ofer
Pelton, Kristine
Hartley, Rachel
Bear, Heather
Georgis, Yohanna
Jarmale, Spandana
Melanson, Randy
Bonanno, Kevin
Schoolcraft, Kathleen
Miller, Peter G.
Condurat, Alexandra L.
Gonzalez, Elizabeth M.
Qian, Kenin
Morin, Eric http://orcid.org/0000-0002-0578-4516
Langhnoja, Jaldeep
Lupien, Leslie E.
Rendo, Veronica
Digiacomo, Jeromy
Wang, Dayle http://orcid.org/0000-0002-2185-1782
Zhou, Kevin http://orcid.org/0000-0003-1567-3606
Kumbhani, Rushil
Guerra Garcia, Maria E.
Sinai, Claire E.
Becker, Sarah
Schneider, Rachel
Vogelzang, Jayne
Krug, Karsten
Goodale, Amy
Abid, Tanaz
Kalani, Zohra
Piccioni, Federica http://orcid.org/0000-0003-1210-3210
Beroukhim, Rameen http://orcid.org/0000-0001-6303-3609
Persky, Nicole S.
Root, David E. http://orcid.org/0000-0001-5122-861X
Carcaboso, Angel M. http://orcid.org/0000-0002-8485-426X
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Fuller, Christine
Babur, Ozgun
Kieran, Mark W.
Jones, Chris
Keshishian, Hasmik
Ligon, Keith L.
Carr, Steven A.
Phoenix, Timothy N. http://orcid.org/0000-0003-4771-4003
Bandopadhayay, Pratiti
- License Information
-
More Information
Article History
Received: 3 December 2020
Accepted: 7 January 2022
First Online: 1 February 2022
Competing interests
: R.B. and P.B. receive grant funding from the Novartis Institute of Biomedical Research for an unrelated project. P.B. has received grant funding from Deerfield and reports a consulting role for QED Therapeutics, R.B. reports consulting or advisory role for Novartis, Merck (I), Gilead Sciences (I), ViiV Healthcare (I); research funding from Novartis; patents, royalties, other intellectual property—Prognostic Marker for Endometrial Carcinoma (US patent application 13/911456, filed June 6, 2013), SF3B1 Suppression as a Therapy for Tumors Harboring SF3B1 Copy Loss (international application No. WO/2017/177191, PCT/US2017/026693, filed July 4, 2017), Compositions and Methods for Screening Pediatric Gliomas and Methods of Treatment Thereof (international application No. WO/2017/132574, PCT/US2017/015448, filed 1/27/2017). M.W.K. is now an employee of Bristol-Myers Squibb. F.P. is now an employee of Merck Research Laboratories. S.A.C. is a member of the scientific advisory boards of Kymera, PTM BioLabs and Seer and a scientific advisor to Pfizer and Biogen. D.E.R. receives research funding from Abbvie, Jannsen, Merck, and Vir through the Functional Genomics Consortium and serves on the board of directors of Addgene. B.L.E. has received research funding from Celgene and Deerfield. He has also received consulting fees from GRAIL, and he serves on the scientific advisory boards for and holds equity in Skyhawk Therapeutics and Exo Therapeutics. (I) denotes a competing interest involving a first degree relative of the author. All the remaining authors declare no competing interests.
